This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-28 and is reviewed periodically as new material appears.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
=== Hatch Act === On May 16, 2026, a pro-Trump group announced that Hegseth would visit Kentucky to raise support for Ed Gallrein's primary contest against Thomas Massie. Hegseth was accused of violating the Hatch Act, which the White House denied.
Skin grafting, in more rudimentary forms, has been practiced since ancient times. The Ebers Papyrus of ancient Egypt contains a brief treatise on xenografting. Around 500 years later, members of the Hindu Kamma caste are described as performing skin grafts which included the usage of subcutaneous fat. The 2nd century AD Greek philosopher Celsus is also known to have developed a method to reconstruct the foreskins of Jewish men using skin grafts, as circumcision was considered barbaric in Greek and Roman society. More modern uses of skin grafting were described in the mid-to-late 19th century, including Reverdin's use of the pinch graft in 1869; Ollier's and Thiersch's uses of the split-thickness graft in 1872 and 1886, respectively; and Wolfe's and Krause's use of the full-thickness graft in 1875 and 1893, respectively. John Harvey Girdner demonstrated skin graft transplant from a deceased donor in 1880. Today, skin grafting is commonly used in dermatologic surgery. Recently Reverdin's technique is used but with very small wounds (less than 3 mm diameter). Such small wounds heal in a short time without scars. This technique is called SkinDot.
Cob(I)alamin is oxidised to cob(II)alamin about once every 100 methyl transfer cycles, rendering the cob(I)alamin-MTR-enzyme complex inactive. Reactivation of this enzyme complex occurs through reductive remethylation by MTRR, utilizing S-adenosylmethionine as a methyl donor. MTR reactivation can also be NADPH dependent involving two redox proteins, soluble cytochrome b5 and reductase 1. However, this pathway is responsible for a minor role in reactivation, whilst MTRR remains a major contributor in this reductive reactivation. Biological processes influenced by MTRR include:
Sources: en.wikipedia.org
Seven Hezbollah members were killed during the clashes. The IDF shelled Meiss Ej Jabal Hospital, injuring a doctor. Lebanon's Ministry of Public Health condemned the attack, saying that "Israeli authorities were fully responsible for this unjustifiable act, which would have led to catastrophic results", and called for an investigation. The Amal Movement, an ally of Hezbollah, announced that a fighter was killed in a missile attack in the village of Rab El Thalathine which also wounded two other members on 11 November. These were the first casualties from the group since it joined the fighting. On 12 November, Hezbollah anti-tank missile and mortar attacks killed an employee of the Israel Electric Corporation who was conducting repair work and injured 21 other Israelis, including seven IDF members and six of the fatality's colleagues. Hezbollah also struck an IDF bulldozer in a separate attack. The IDF said it had launched a drone strike at a militant cell that tried to launch antitank missiles near Metula. Further clashes also killed one Hezbollah member. Following a Hezbollah strike on 13 November, the IDF responded with heavy shelling across southern Lebanon which reportedly killed two people, according to a first-responder organisation affiliated to the Hezbollah-allied Amal Movement. Unidentified fighters fired anti-tank guided missiles that injured two Israelis near Netu'a. An Israeli rocket struck near journalists in Yaroun, Lebanon, no casualties were reported. Hezbollah condemned the attack, which happened while the journalists were on a public tour in the town.
Y-90, used for treating lymphoma (2.7 days) I-131, used for thyroid function tests and for treating thyroid cancer (8.0 days) Sr-89, used for treating bone cancer, intravenous injection (52 days) Ir-192, used for brachytherapy (74 days) Co-60, used for brachytherapy and external radiotherapy (5.3 years) Cs-137, used for brachytherapy and external radiotherapy (30 years) Tc-99, product of the decay of technetium-99m (221,000 years)
=== Natural Metalloenzymes repurposing === In addition to anchoring artificial metal center in the protein scaffold, researchers like Frances Arnold and Yang Yang focused on changing the native environment of natural metallocofactors. Due to the large sequence space that can be evolved in natural metalloenzymes, they can be evolved to catalyse non-native transformations. This process is known as enzyme repurposing. Directed evolution is commonly used to tailor the catalytic capacity and repurpose the enzyme function. Mostly based on native porphyrin-metallocofactor, Arnold's lab has developed many ArMs catalysing regioselective and/or enantioselective transformations, such as Carbon-Boron bond formation, carbene insertion, and aminohydroxylation by evolving the sequence context of the corresponding ArMs. As the pioneers of metalloredox radical biocatalysis, Yang et al. repurposed cytochrome P450s to catalyze atom transfer radical cyclization (ATRC), and Huang et al. repurposed non-heme Fe-dependent enzymes to catalyze an abiological radical-relay azidation and radical fluorination.
It also has the largest Brazilian community in the UK; one of the largest Indian communities; a significant Afro-Caribbean community; and more recent Romanian, Polish and Somali communities. The 2021 census showed that 1.3% of adults in Brent identified as transgender, derived from the Census question, "Is the gender you identify with the same as your sex registered at birth?". This gave Brent the second highest proportion of transgender adults after the Borough of Newham (at 1.5%). The overall proportion in England and Wales was 0.5% with Brighton, an area well known for its LGBT communities, 1%. However, Prof Michael Biggs of Oxford University showed there was a correlation between the proportion of transgender people in these areas and the proportion for whom English was not their first language (34% in Brent and 35% in Newham, compared to 9% nationally), suggesting the question was not fully understood by some. Prof Biggs described the figures as "irredeemably flawed". In September 2024, Mary Gregory, a deputy director at the ONS said some people may have misunderstood the question, saying there was "potential bias" in how the question was answered "by those who responded that they had lower levels of English proficiency, some of whom may have mistakenly given an answer suggesting they were trans". As a result, the ONS downgraded the data from "accredited official statistics" to "official statistics in development" to reflect the possible flaws.
Sources: en.wikipedia.org
Mulliken (1896–1986), American physicist and chemist known for molecular orbital theory, 1966 Nobel Prize in Chemistry Jnanendra Nath Mukherjee(1893-1983), Indian chemist known for work on the electrochemistry of colloids Kary Mullis (1944–2019), American biochemist who invented the polymerase chain reaction, 1993 Nobel Prize in Chemistry Earl Muetterties (1927–1984), American chemist known for work on boranes and various aspects of catalysis Catherine J. Murphy (born 1964), American chemist and materials scientist known for work on nanomaterials
Hans-Joachim Merker (7 October 1929 – 18 August 2014) was a German physician and anatomist. He was Professor of Anatomy at the Free University of Berlin from 1972 to 1998, and served as Dean of the Faculty of Medicine from 1980 to 1981. He was noted for his research on the fine structure of connective tissue, the morphology of hormone effects, and embryological and embryotoxic problems, and his research was central in the development of medical research utilising electron microscopy. Hans Georg Baumgarten noted on his death that he was "not only a chair-holder, but a philosopher, humanist, anthropologist, developmental biologist, transdisciplinary scholar and scientist".
== RNAi == Interfering RNA are a class of short, noncoding RNA that act to translationally or post-translationally repress gene expression. Their discovery and subsequent identification as key effectors of post-transcriptional gene regulation have made small interfering RNA (siRNA) and micro RNA (miRNA) potential therapeutics for systemic diseases. The RNAi system was originally discovered in 1990 by Jorgensen et al., who were doing research involving the introduction of coloration genes into petunias, and it is thought that this system originally developed as a means of innate immunity against double-stranded RNA viruses.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.